TCRT - Alaunos Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

TCRT

ALAUNOS THERAPEUTICS, INC.

NASDAQ

$1.60

▼ DOWN 3.31% (-0.06)

KEY STATISTICS

Market Cap$3.92 M

52w High$4.59

52w Low$1.55

Dividend Yield—

Frequency—

P/E-0.82

Volume35.72K

Shares Out.2.44M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Holger Weis

COMPENSATION 2026

Salary$573,000

Stock Awards$755,476

Incentive Plan Pay$0

All Other Comp.$94,991

Total$3,317,574

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 24, 2005

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 17, 2026

DayTuesday

Rev. Est.—

NOV

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2024-07-18	Reverse	1:10
2024-02-01	Reverse	1:15
2005-08-24	Reverse	1:40

PRICE

$1.60 ▼ DOWN 3.31% (−$0.06)

OVERLAYS

About Alaunos Therapeutics, Inc.

https://www.alaunos.com ↗

Alaunos Therapeutics, Inc. is a Houston-based clinical-stage oncology company developing adoptive TCR-engineered T-cell therapies, including a Phase I/II TCR Library targeting multiple cancers and neoantigen platforms.

INDUSTRY

Biotechnology

A PRODUCT ALAUNOS THERAPEUTICS, INC. IS KNOWN FOR

Preclinical small molecule for obesity and metabolic disorders

This is a preclinical oral drug candidate being developed for the treatment of obesity and other metabolic diseases. It represents Alaunos Therapeutics' current primary focus after discontinuing its previous oncology programs.